호르몬 불응성 전립선암 환자의 생존율 및 예후인자 = Survival Rates and Related Factors in Men with Hormone-Refractory Prostate Cancer

다국어 초록 (Multilingual Abstract)

Purpose: We evaluated survival rate in patients with hormone-refractory prostate cancer (HRPC) and the clinical factors that influenced survival rate and time.
Materials and Methods: The medical records of 96 patients who had HRPC and were not treated with chemotherapy from 2000 to 2008 were reviewed. We evaluated the survival rates at the 1st, 3rd, and 5th year by using Kaplan-Meier survival curves. We also evaluated survival differences according to clinical variables (clinical T stage, Gleason score, nadir prostate-specific antigen [PSA], PSA doubling time, and PSA velocity) by using the log-rank test and the relations between survival rates and these variables by using Cox proportional hazards models.
Results: The mean age of the patients was 67.8±7.5 years and the mean follow-up period was 23.3±13.7 months. Cancer-specific survival rates at the 1st, 3rd, and 5th year were 57.8%, 16.8%, and 10.1%, respectively, and survival differences were significantly related to nadir PSA (p=0.002) and PSA velocity (p=0.019). In the univariate analysis, nadir PSA (p=0.004) and PSA velocity (p=0.024) were related to survival rate, but only nadir PSA remained as a significant variable for survival rate in patients with HRPC in the multivariate analysis (p=0.044).
Conclusions: Cancer-specific survival rates in patients with HRPC at the 1st, 3rd, and 5th year were 57.8%, 16.8%, and 10.1%, respectively, and they were related to nadir PSA. These results may be useful in determining a therapeutic approach in patients with HRPC.

다국어 초록 (Multilingual Abstract)

Purpose: We evaluated survival rate in patients with hormone-refractory prostate cancer (HRPC) and the clinical factors that influenced survival rate and time.
Materials and Methods: The medical records of 96 patients who had HRPC and were not treated with chemotherapy from 2000 to 2008 were reviewed. We evaluated the survival rates at the 1st, 3rd, and 5th year by using Kaplan-Meier survival curves. We also evaluated survival differences according to clinical variables (clinical T stage, Gleason score, nadir prostate-specific antigen [PSA], PSA doubling time, and PSA velocity) by using the log-rank test and the relations between survival rates and these variables by using Cox proportional hazards models.
Results: The mean age of the patients was 67.8±7.5 years and the mean follow-up period was 23.3±13.7 months. Cancer-specific survival rates at the 1st, 3rd, and 5th year were 57.8%, 16.8%, and 10.1%, respectively, and survival differences were significantly related to nadir PSA (p=0.002) and PSA velocity (p=0.019). In the univariate analysis, nadir PSA (p=0.004) and PSA velocity (p=0.024) were related to survival rate, but only nadir PSA remained as a significant variable for survival rate in patients with HRPC in the multivariate analysis (p=0.044).
Conclusions: Cancer-specific survival rates in patients with HRPC at the 1st, 3rd, and 5th year were 57.8%, 16.8%, and 10.1%, respectively, and they were related to nadir PSA. These results may be useful in determining a therapeutic approach in patients with HRPC.

참고문헌 (Reference)

1 박범진, "전이성 전립선암의 호르몬 치료 2개월 후 전립선특이항원 치의 예후적 의의" 대한비뇨기과학회 44 (44): 855-860, 2003

2 김기호, "전이성 전립선암 환자에서 내분비요법 후 예후에 영향을 미치는 인자" 대한비뇨기과학회 45 (45): 24-28, 2004

3 Morote J, "Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer" 20 : 209-216, 2005

4 Oefelein MG, "Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era" 171 : 1525-1528, 2004

5 Rozhansky F, "Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma" 106 : 63-67, 2006

6 Semeniuk RC, "Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer" 68 : 565-569, 2006

7 Oudard S, "Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone- refractory prostate cancer patients" 18 : 1828-1833, 2007

8 Collette L, "Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)" 44 : 182-189, 2003

9 Kwak C, "Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer patients" 42 : 948-953, 2001

10 Matzkin H, "Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer" 70 : 2302-2309, 1992

11 Eisenberger MA, "Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036" 21 : 613-619, 1994

12 D'Amico AV, "Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy" 294 : 440-447, 2005

13 Robinson D, "PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer" 72 : 903-907, 2008

14 Smaletz O, "Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration" 20 : 3972-3982, 2002

15 Heidenreich A, "EAU guidelines on prostate cancer" 53 : 68-80, 2008

16 Eisenberger MA, "Chemotherapy for hormone-resistant prostate cancer, in Campbell's urology. 7th ed" Saunders 2648-2658, 1988

17 Mike S, "Chemotherapy for hormone-refractory prostate cancer" 4 : CD005247-, 2006

18 Korea Central Cancer Registry, Ministry for Health Welfare and Family Affairs, "Annual report of the central cancer registry in Korea" National Cancer Center 2003